Jul 07
Congratulations to Nallathamby lab’s @JohannaOlesk on successfully defending her Masters thesis for Bioengineering in Summer 2023. Her thesis was titled ” Phage-Mimicking Nanoparticles Conjugated with Antimicrobial Peptides and Polymers as an Alternative to Antibiotic Treatment.” She passed with unanimous consent. We wish her all the best in her future undertakings. #WomenInSTEM#notredame#GoIrish Special mention to all …
Jun 17
We were excited to present our work titled, “Biomimetic, Antibiotic Free, Nanoparticles for Agent Agnostic Broad Spectrum Antimicrobial Action including ESKAPE Pathogens” [Abstract 557] at the 2023 TechConnect World Innovation Conference in National Harbor, MD (June 19-21, 2023), as part of the Precision Health and Diagnostics symposium. Our talk was well received. We got lots of useful …
May 23
Nallathamby group’s work on “Phage-mimicking, Broad-spectrum, antibacterial nanoparticles” was showcased at MTEC’s annual meeting in Richmond, Virginia. I am proud to represent Notre Dame and the Berthiaume Institute for Precision Health at the 8th annual meeting of MTEC to learn firsthand the medical needs of the DoD. Our focus on combating antimicrobial resistance using phage …
May 01
Congratulations to @Argerie Guevara (CBE’23) for taking the thesis option in her undergraduate research and passing it with unanimous consensus today. Her thesis was titled, “PLGA nanoparticles formulations loaded with antibiotics induce sustained and controlled antibiotics release for prolonged antibacterial action against MRSA, and Pseudomonas aeruginosa FRD1,” and is currently being peer-reviewed for publication. Argerie is currently …
Nov 16
In recent combat theaters, despite advances in treating critical injuries leading to higher survival rates, there has been an increase in the number of infections linked to trauma, particularly those caused by bacteria resistant to multiple drugs 1,2. Research from the Trauma Infectious Disease Outcomes Study indicates that 27% of those evacuated with injuries develop …
Sep 16
We are losing in an antibiotic arms race with bacteria due to the emergence and global spread of new antibiotic resistance mechanisms.1,2 At current rates of antibiotics discovery and development we will eventually lose to antibiotic-resistant strains, and by 2050, antibiotics resistant strains of bacteria will kill more patients per year than all cancers combined. …
Jul 07
Breast Cancer is the most widespread cancer and the second leading cause of cancer-related deaths among women in the U.S.A. As a treatment option, gene-modified T cells are under active therapeutic consideration for both hematological and solid malignancies. As of 2016, there are 17 active TCR and 103 ongoing CAR-modified T cell studies registered through …
May 14
Our research looks at the basic mechanism of drug resistance in bacteria or cancer cells and then we work on translational solutions to combat these problems. Our approach felt validated at this meeting where we networked with industry end-users as well as disease-on-a chip modeling academicians.
Jan 09
Virtually presented our lab’s research on tackling two pressing problems in biomedical research at the Society for Biomaterials/ Japanese Society for Biomaterials joint Symposium in Honolulu, Hawaii. (January 8-10, 2022). I am presenting our research on broad-spectrum antibiotic-free antibacterials to combat multi-drug resistant bacterial infections. Oral Presentation Session: Session 1: Bioglasses/Ceramics/Other Hard Materials2:37 – 2:52 …
Sep 02
The University of Notre Dame’s Institute for Precision Health (IPH) has awarded funding to researchers spanning multiple departments at the University, as well as to colleagues at partner schools. IPH awarded proposals with two types of funding: seed grants, which provide funding for high-risk, high-reward research ideas, and harvest grants, which help researchers expand on established projects or pursue …
NIH Funding Opportunities
Recent Comments